Komori
Pharma Foods International (2929) · TargetDropped

¥30 billion sales target for Newmo hair-growth products for the current fiscal year

First written in FY2022-Q1. 5 of 8 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2024.

8entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q2 – FY2023-Q2OtherFY2023 – FY20242021: 12022: 420222023: 220232024: 12024
Same theme, other companies
Sales target for the ニューモ hair-growth treatmentA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024DroppedAnnual report

    「Cumulative shipments of the Newmo hair-growth product exceeded 27 million units as of 4 June 2024.」

    The previously established current-year revenue target of ¥30 billion was not reiterated in this filing, which instead reported cumulative shipments and the contribution of the Newmo product range to earnings.
  2. FY2023Below the ¥30,000 million targetAnnual report

    「Revenue from the Newmo hair-growth product was ¥27,967 million, up 4.5% year on year.」

    Against the current-year revenue target of ¥30,000 million, full-year revenue was ¥27,967 million, falling short of the target.
  3. FY2023-Q2AdvancedAnnual report

    「Cumulative shipments of the Newmo hair-growth product exceeded 18 million units as of 24 December 2022, and orders have continued at a solid pace.」

    Cumulative shipments of the Newmo hair-growth product increased from the previous 17 million units to 18 million units, expanding the sales base related to the current-year revenue target.
  4. FY2023-Q1AdvancedAnnual report

    「Cumulative shipments of the Newmo® hair-growth product exceeded 17 million units as of 5 November 2022, and orders have continued at a solid pace.」

    As a sales base related to the current-year revenue target of ¥30 billion, cumulative shipments advanced from 15 million to 17 million units.
  5. FY2022AdvancedAnnual report

    「Revenue from the Newmo® hair-growth product was ¥27,967 million, up 4.5% year on year. The number of subscription customers remained high at 441,403, contributing to higher group-wide revenue and profit through increased repeat purchases. Cumulative shipments of the Newmo® hair-growth product exceeded 15 million units as of 23 July 2022.」

    Against the current-year revenue target of ¥30 billion, full-year revenue was ¥27.967 billion. Subscription customers numbered 441,403 and cumulative shipments reached 15 million units, but the target was not achieved.
  6. FY2022-Q3AdvancedAnnual report

    「Revenue from the Newmo® hair-growth product was ¥21,834 million for the cumulative third quarter of the current consolidated fiscal year. Cumulative shipments of the Newmo® hair-growth product exceeded 13 million units as of 5 April 2022, and orders have continued at a solid pace. The company is targeting revenue of ¥30,000 million for the current fiscal year.」

    Against the current-year revenue target of ¥30 billion, cumulative third-quarter revenue was ¥21.834 billion and cumulative shipments reached 13 million units.
  7. FY2022-Q2AdvancedAnnual report

    「Revenue from the Newmo® hair-growth product was ¥14,913 million for the cumulative second quarter of the current consolidated fiscal year. The number of subscription customers remained high at 520,958, contributing to higher group-wide revenue and profit through increased repeat purchases. Cumulative shipments of the Newmo® hair-growth product exceeded 12 million units as of 17 February 2022, and orders have continued at a solid pace. The company is targeting revenue of ¥30,000 million for the current fiscal year.」

    Against the current-year revenue target of ¥30 billion, cumulative second-quarter revenue was ¥14,913 million, cumulative shipments were 12 million units and subscription customers numbered 520,958.
  8. FY2022-Q1First statedAnnual report

    「Revenue from the Newmo® hair-growth product was ¥7,431 million for the cumulative first quarter of the current consolidated fiscal year. The number of subscription customers remained high at 543,602, contributing to higher company-wide revenue and profit through increased repeat purchases. Cumulative shipments of the Newmo® hair-growth product exceeded 10 million units as of 15 November 2021. The company is targeting revenue of ¥30,000 million for the current fiscal year.」

    For the Newmo hair-growth product, the company stated for the first time a current-year revenue target of ¥30 billion, against cumulative shipments of 10 million units, first-quarter revenue of ¥7,431 million and 543,602 subscription customers.
Moved together

"Advertising Investment and Product Brand Expansion in Mail-Order Sales" moved the same way as this thread, in the same document, in 5 of its 8 moves.

555444★123456
  1. ★This thread
  2. 1Advertising Investment and Product Brand Expansion in Mail-Order Sales5×
  3. 2Raising Working Capital through Borrowings5×
  4. 3 적극ive efforts under the Foods with Function Claims system5×
  5. 4Development of antibody therapeutics using proprietary chicken antibody technology4×
  6. 5Aggressive business investment aimed at sustained long-term growth and increased corporate value4×
  7. 6Functional Materials business: lower revenue and profit4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.